These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12390317)

  • 1. Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection.
    Burton CT; Hardy GA; Sullivan AK; Nelson MR; Gazzard B; Gotch FM; Imami N
    Clin Exp Immunol; 2002 Nov; 130(2):286-92. PubMed ID: 12390317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART.
    Wasmuth JC; Nischalke HD; Jütte A; Fätkenheuer G; Salzberger B; Sauerbruch T; Spengler U; Rockstroh JK; Dumoulin FL
    Antiviral Res; 2004 Mar; 61(3):207-12. PubMed ID: 15168802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy.
    De Luca A; Giancola ML; Cingolani A; Ammassari A; Murri R; Antinori A
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):835-43. PubMed ID: 10875609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
    Carter LM; Peters BS; Ellis BA; Wolstencroft RA
    J Infect; 2000 Nov; 41(3):252-5. PubMed ID: 11120614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
    Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
    Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir.
    Bisset LR; Rothen M; Joller-Jemelka HI; Dubs RW; Grob PJ; Opravil M
    AIDS; 1997 Mar; 11(4):485-91. PubMed ID: 9084796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy.
    Giovannetti A; Ensoli F; Mazzetta F; De Cristofaro M; Pierdominici M; Muratori DS; Fiorelli V; Aiuti F
    Clin Exp Immunol; 1999 Oct; 118(1):87-94. PubMed ID: 10540164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta.
    Kumar D; Parato K; Kumar A; Sun E; Cameron DW; Angel JB
    AIDS Res Hum Retroviruses; 1999 Aug; 15(12):1073-7. PubMed ID: 10461827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
    Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
    Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy.
    Blanco J; Cabrera C; Jou A; Ruiz L; Clotet B; Esté JA
    AIDS; 1999 Apr; 13(5):547-55. PubMed ID: 10203379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
    J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases.
    Ghani AC; Henley WE; Donnelly CA; Mayer S; Anderson RM
    AIDS; 2001 Jun; 15(9):1133-42. PubMed ID: 11416715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.
    Blanpain C; Migeotte I; Lee B; Vakili J; Doranz BJ; Govaerts C; Vassart G; Doms RW; Parmentier M
    Blood; 1999 Sep; 94(6):1899-905. PubMed ID: 10477718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kryst J; Kawalec P; Pilc A
    PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sullivan AK; Burton CT; Nelson MR; Moyle G; Mandalia S; Gotch FM; Gazzard BG; Imami N
    Scand J Immunol; 2003 Jun; 57(6):600-7. PubMed ID: 12791099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.